BrightSpring Health Services UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everybody. Next up in here is BrightSpring Health Services. We are excited to have Jon Rousseau, President and Chief Executive Officer, and Jennifer Phipps, Chief Financial Officer, with us. Thanks for doing the conference this year. We are 10 months into the year. Can you give us an assessment of the company's performance year to date? What has been positive, challenges, any surprises?
Yeah. Good morning, AJ. Good morning, everybody. It is a pleasure to be here. Yeah, it has been a productive year for the company again. I would say at this point, we have got a 10-year CAGR north of right around 20% on both revenue and EBITDA. That number has been more elevated over the past three or four years. But it has been a continuation of a long-term strategy around volume growth, efficiency, and doing some accretive M&A here and there within markets in home and community healthcare we really like. That has played out again this year. Throughout the course of the year, our performance has been on or a little bit ahead of even our internal plan for numerous reasons. Again, volume growth has been really strong. I think that has been underpinned by our quality data that we have continued to invest in over time.
I would say one thing that has continued to play out very well for us is a lot of things from a process perspective and a lean perspective. We have continued to lean into investments in technology, people, and process, and we are seeing the benefits of that, particularly in one or two of our businesses in the company throughout the year. I would say when we see growth like we have this year, we have continued to invest across the board for future growth as well. I mean, we are continually trying to think about long-term durable growth within the organization. I think all of it ultimately, though, comes back to the fact that we provide services that are really valuable. People generally want to be seen more in the home and community. What we do has really high quality, and it has a dramatically lower cost to it.
We are a leader in U.S. home and community healthcare. We think that is a really good place to be. Within home and community healthcare, we specifically target three pharmacy and three provider end markets that we like the most, and those services have tremendous value. If we can continue to build scale, have leading quality of services, and execute as best we can on the commercial side, that is what we have been working on creating and continue to create over the past decade. And I think the performance this year is a continuation of a lot of the hard work in the prior years.
No, that's great. Infusion specialty revenues have grown roughly 34% in the third quarter. Can you talk about the growth, the different sub-components, areas like oncology, rare and orphan, and infusion, and what you're seeing?
Yeah, certainly a lot of innovation in these therapeutic areas that we provide services in and partner with manufacturers and payers. Oncology continues. The biotechs, the manufacturers are innovating to a great degree, and a lot of just incredible life-saving and life-altering therapies that come to market. With our service offerings, we do our best to partner with those upstream manufacturers and biotechs to deliver the best possible quality and outcomes for their patients. Positioning ourselves within these dynamic therapeutic markets has been positive, and we continue to see very robust long-term trends there. You look at things like net promoter score, medication adherence, a lot of our wraparound services, we've just really invested and tried to do our best to be the best possible provider partner so we can help to bring these therapies to as many people as possible.
These are big end markets that continue to grow with therapies that are critically needed, and again, just continuing to invest in the platform, which really started about 15 years ago in those businesses in particular. So, continuing to see very robust growth there, primarily volume-driven, and continuing to invest in efficiency in these businesses as well. But we see a long-term pathway there to continue to be a partner and scale in these markets.
Great. Can you remind us limited distribution drug pipeline moving forward, how that will benefit that segment's growth trajectory?
Yeah. We have been honored to be selected as an exclusive or an ultra-narrow partner with manufacturing partners when they launch drugs over the past three or four years. Really everything we have done has been in an exclusive or ultra-narrow relationship. We see that continuing. This year, we will be right around 20 new launches into the market, partnering with the brands to commercialize those, and we look at the pipeline in a very similar way. We have got a pretty longstanding history with a lot of the manufacturers out there, and we do our best to work with them well ahead of time to maximize the success of these therapies for prescribers and for patients and their families.
That track record that we have been executing on for about the last three years, that has been very consistent again this year, and we see the same thing next year and in the near future.
Do you have a pretty good visibility on those new drug launches at this point, or say at the beginning of this year, would you have been surprised by how many you have ended up seeing this year?
Yeah. No, I think we have had good visibility, usually about 12 months out. I think we have really good predictability and visibility on that. Obviously, that is just a function of the innovation that is coming to market, and we do our best to position ourselves to maximize the success for everybody when those events do occur. But usually we have pretty good visibility at looking out about a year.
Okay. Infusion has been an area you have invested in. You have upgraded the management team over the last few years. Can you talk about the opportunities there, particularly in Well, you might describe that there is the two business segments, but acute, I know, is something you have highlighted the opportunity. Are you making above average investments in that area today that may moderate over time as you see the results?
Yeah, I would say we have continued to make people and IT investments in the infusion business. It is one that we see great potential with. Again, our strategy is one that I think is a little bit more comparatively broad to some of the other mid-market companies out there. We like acute. It is an area that is more difficult, where there are fewer providers, but it is incredibly necessary and needed. We also like areas of specialty chronic infusion too, which we are focusing on. Historically, we have been more tilted to the acute side, just based on what the company was going back 30 years ago. Again, we think that is a critically important area of infusion. That is very stable, not going anywhere. We will continue to invest on the chronic side as well as best we can.
The volume performance in that business has been very solid all year, well into the double-digit growth. Those are our aspirations for next year too. The infusion market is a $20 billion market. Whether it is on the acute side or the chronic side, in the home or in clinics, we ultimately have that broader vision for acute, to maximize volume potential in our scale. We see that business as continuing to be a growing contributor to our EBITDA breakdown as we go forward into the future. So, good momentum there and very important to the future of the company.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
